Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Oslo Bors  >  VACY AS    VACC   NO0010714785

VACY AS

(VACC)
  Report
 SummaryQuotesNewsCalendarCompanyFinancialsConsensusRevisions 
Financials
Sales 2018 12,0 M 1,38 M 1,38 M
Net income 2018 -63,8 M -7,29 M -7,29 M
Net cash position 2018 144 M 16,4 M 16,4 M
P/E ratio 2018 -
Yield 2018 -
Sales 2019 12,4 M 1,42 M 1,42 M
Net income 2019 -96,0 M -11,0 M -11,0 M
Net cash position 2019 277 M 31,7 M 31,7 M
P/E ratio 2019 -
Yield 2019 -
Capitalization 17 215 M 1 950 M 1 967 M
EV / Sales 2018 -
EV / Sales 2019 -
Nbr of Employees 36
Free-Float 97,2%
More Financials
Company
Vaccibody AS is a Norway-based vaccine company. It is engaged in the development of vaccines that overcome the shortcomings of current vaccine technologies. The Company's vaccine platform increases the antibody and T-cell responses. The Company focuses on cancer vaccines, partnering the technology within infection and veterinary use. The Company develops of an immuntherapy against HPV-induced malignancies, such as... 
More about the company
All news about VACY AS
11/17VACCIBODY AS : - Quarterly report 3Q 2020
AQ
11/12VACY : Mandatory notification of trade - party related to primary insider
AQ
11/12VACY : Vaccibody to present at Jefferies Virtual Healthcare Conference (November..
AQ
11/06VACY : Vaccibody announces the closing of the worldwide license and collaboratio..
AQ
10/22VACY : Mandatory notification of trade - primary insider
AQ
10/07VACY : Mandatory notification of trade - primary insider
AQ
10/07VACCIBODY AS : Lists on Oslo Stock Exchange's Merkur Market
AQ
10/07VACY : Financial calendar
AQ
10/05VACY : Merkur Market - Received application for admission to trading - Vaccibody..
AQ
More news
News in other languages on VACY AS

- No features available -

More news
Chart VACY AS
Duration : Period :
VACY AS Technical Analysis Chart | VACC | NO0010714785 | MarketScreener
Income Statement Evolution
Consensus
 
Mean consensus -
Number of Analysts
Average target price
Last Close Price 60,50 
Spread / Highest target -
Spread / Average Target -
Spread / Lowest Target -
EPS Revisions
Managers
NameTitle
Michael Thyrring Engsig Chief Executive Officer
Agnete Brunsvik Fredriksen President & Chief Scientific Officer
Anders Tuv Chairman
Charlotte Qwist Director-Clinical Development & Operations
Lars Dencker Nielsen Chief Financial Officer
Sector and Competitors
1st jan.Capitalization (M$)
VACY AS0.00%1 950
GILEAD SCIENCES, INC.-5.92%76 628
VERTEX PHARMACEUTICALS3.54%58 951
REGENERON PHARMACEUTICALS34.64%53 359
WUXI APPTEC CO., LTD.64.21%39 880
BIONTECH SE257.41%29 157